Growth In ANDA Submissions Is Leveling Off, OGD Director Says
This article was originally published in The Pink Sheet Daily
While still growing and setting records, change in pace of submissions could give FDA "breather" to work on backlog.
You may also be interested in...
GPhA says it would consider user fees for generics if FDA would endorse legislation to speed generics to the market.
Our infographic offers a composite sketch from a decade of US FDA data on refuse-to-file letters.
Pink Sheet reporters and editor discuss the issues surrounding an FDA warning letter on Dsuvia promotion, an expected jump in CDER coronavirus-related workload, and a study of refuse-to-file actions.